Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

CD20 Antibodies of Human IgA Isotype Mediate CDC, and ADCC By Myeloid Effector Cells

Anna Kretschmer, Stefan Lohse, PhD, Thies Rösner, PhD, Marco J.H. Jansen, Christian Kellner, PhD, Matthias Peipp, PhD, Mark S Cragg, PhD, Ameera Alsadeq, PhD, Denis M Schewe, MD, Jeanette H.W. Leusen, PhD, Thomas Valerius, MD

Blood (2016) 128 (22): 1835.

https://doi.org/10.1182/blood.V128.22.1835.1835

Published: 2016

Journal Articles

Switching from IgG1 to IgG3 Isotype to Boost Complement-Activating Capacities of Therapeutic Antibodies – Impact of CD55 Expression on the Mode of Action

Stefanie Derer, PhD, Thies Rösner, Stefan Lohse, PhD, Matthias Peipp, PhD, Thomas Valerius, MD

Blood (2014) 124 (21): 3506.

https://doi.org/10.1182/blood.V124.21.3506.3506

Published: 2014

Journal Articles

Ratios Of FcγRIIa and FcγRIII Binding Affinities Govern The Efficacy Of PMN-Mediated Cytotoxicity – Implications For Fc-Engineering Approaches Of Therapeutic Antibodies

Stefanie Derer, PhD, Pia Glorius, PhD, Martin Schlaeth, Stefan Lohse, PhD, Umesh Muchhal, Ph.D., John Desjarlais, Andreas Humpe, MD, Thomas Valerius, MD, Matthias Peipp, PhD

Blood (2013) 122 (21): 3466.

https://doi.org/10.1182/blood.V122.21.3466.3466

Published: 2013

Journal Articles

Recombinant Dimeric IgA Antibodies as Tumor-Specific Agents.

Michael Dechant, MD, Stefan Lohse, PhD, Stefanie Derer, PhD, Thomas Beyer, PhD, Katja Klausz, PhD, Matthias Peipp, PhD, Jeanette H. W. Leusen, PhD, Jan G. J. van de Winkel, PhD, Thomas Valerius, MD

Blood (2010) 116 (21): 1488.

https://doi.org/10.1182/blood.V116.21.1488.1488

Published: 2010

Journal Articles

Recombinant Chimeric IgA1 and IgA2 Antibodies for Tumor Immunotherapy.

Michael Dechant, MD, Thomas Beyer, PhD, Stefan Lohse, Tanja Schneider-Merck, PhD, Wencke Weisner, Sven Berger, PhD, Matthias Peipp, PhD, Jan G.J. van de Winkel, PhD, Thomas Valerius, MD

Blood (2007) 110 (11): 4892.

https://doi.org/10.1182/blood.V110.11.4892.4892

Published: 2007

NARROW

CD20 Antibodies of Human IgA Isotype Mediate CDC, and ADCC By Myeloid Effector Cells

Switching from IgG1 to IgG3 Isotype to Boost Complement-Activating Capacities of Therapeutic Antibodies – Impact of CD55 Expression on the Mode of Action

Ratios Of FcγRIIa and FcγRIII Binding Affinities Govern The Efficacy Of PMN-Mediated Cytotoxicity – Implications For Fc-Engineering Approaches Of Therapeutic Antibodies

Recombinant Dimeric IgA Antibodies as Tumor-Specific Agents.

Recombinant Chimeric IgA1 and IgA2 Antibodies for Tumor Immunotherapy.

Email alerts

ASH Publications

American Society of Hematology

CD20 Antibodies of Human IgA Isotype Mediate CDC, and ADCC By Myeloid Effector Cells

Switching from IgG1 to IgG3 Isotype to Boost Complement-Activating Capacities of Therapeutic Antibodies – Impact of CD55 Expression on the Mode of Action

Ratios Of FcγRIIa and FcγRIII Binding Affinities Govern The Efficacy Of PMN-Mediated Cytotoxicity – Implications For Fc-Engineering Approaches Of Therapeutic Antibodies

Recombinant Dimeric IgA Antibodies as Tumor-Specific Agents.

Recombinant Chimeric IgA1 and IgA2 Antibodies for Tumor Immunotherapy.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only